672 related articles for article (PubMed ID: 27729297)
1. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C; Dingemans AC; Gray JE; Nakagawa K; Nicolson M; Peters S; Reck M; Wu YL; Brustugun OT; Crinò L; Felip E; Fennell D; Garrido P; Huber RM; Marabelle A; Moniuszko M; Mornex F; Novello S; Papotti M; Pérol M; Smit EF; Syrigos K; van Meerbeeck JP; van Zandwijk N; Yang JC; Zhou C; Vokes E
J Thorac Oncol; 2017 Feb; 12(2):194-207. PubMed ID: 27729297
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study.
Yao J; Wang Z; Sheng J; Wang H; You L; Zhu X; Pan H; Han W
Int Immunopharmacol; 2020 Dec; 89(Pt A):107033. PubMed ID: 33039958
[TBL] [Abstract][Full Text] [Related]
3. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
Qiang H; Chang Q; Xu J; Qian J; Zhang Y; Lei Y; Han B; Chu T
J Cancer Res Clin Oncol; 2020 Mar; 146(3):631-645. PubMed ID: 32065262
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
Reck M; Garassino MC; Imbimbo M; Shepherd FA; Socinski MA; Shih JY; Tsao A; Lee P; Winfree KB; Sashegyi A; Cheng R; Varea R; Levy B; Garon E
Lung Cancer; 2018 Jun; 120():62-69. PubMed ID: 29748017
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019.
Cantelmo AR; Dejos C; Kocher F; Hilbe W; Wolf D; Pircher A
Curr Opin Oncol; 2020 Jan; 32(1):44-53. PubMed ID: 31609741
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives.
Reck M; Popat S; Grohé C; Corral J; Novello S; Gottfried M; Brueckl W; Radonjic D; Kaiser R; Heymach J
Lung Cancer; 2023 May; 179():107173. PubMed ID: 36940614
[TBL] [Abstract][Full Text] [Related]
8. The safety of second-line treatment options for non-small cell lung cancer.
Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
[TBL] [Abstract][Full Text] [Related]
9. The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future.
Shukla NA; Yan MN; Hanna N
Clin Lung Cancer; 2020 Jul; 21(4):308-313. PubMed ID: 32291211
[TBL] [Abstract][Full Text] [Related]
10. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
11. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
12. Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
Pircher A; Wolf D; Heidenreich A; Hilbe W; Pichler R; Heidegger I
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088109
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
[TBL] [Abstract][Full Text] [Related]
16. First-line combination immunotherapy for metastatic non-small cell lung cancer.
Chen YM
J Chin Med Assoc; 2020 May; 83(5):433-441. PubMed ID: 32132380
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.
Wozniak A
Crit Rev Oncol Hematol; 2012 May; 82(2):200-12. PubMed ID: 21715183
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]